Abstract

Whether environmental lead exposure has a long-term effect on progressive diabetic nephropathy in type II diabetic patients remains unclear. A total of 107 type II diabetic patients with stage 3 diabetic nephropathy (estimated glomerular filtration rate (eGFR) range, 30–60 mL/min/1.73 m2) with normal body lead burden (BLB) (<600 μg/72 hr in EDTA mobilization tests) and no history of exposure to lead were prospectively followed for 2 years. Patients were divided into high-normal BLB (>80 μg) and low-normal BLB (<80 μg) groups. The primary outcome was a 2-fold increase in the initial creatinine levels, long-term dialysis, or death. The secondary outcome was a change in eGFR over time. Forty-five patients reached the primary outcome within 2 years. Although there were no differences in baseline data and renal function, progressive nephropathy was slower in the low-normal BLB group than that in the high-normal BLB group. During the study period, we demonstrated that each 100 μg increment in BLB and each 10 μg increment in blood lead levels could decrease GFR by 2.2 mL/min/1.72 m2 and 3.0 mL/min/1.72 m2 (P = 0.005), respectively, as estimated by generalized equations. Moreover, BLB was associated with increased risk of achieving primary outcome. Environmental exposure to lead may have a long-term effect on progressive diabetic nephropathy in type II diabetic patients.

Highlights

  • Over the past 25 years, the prevalence of type II diabetes in the USA has almost doubled, with 3- to 5-fold increases in developing countries [1]

  • The following baseline data were obtained: patient mean age, 60.1 ± 9.5 years; body-mass index, 24.9 ± 3.3; serum creatinine level, 1.9 ± 0.3 mg/dL; estimated glomerular filtration rate (eGFR), 41.3 ± 6.9 mL/min/1.73 m2 of body surface area; daily protein excretion, 3.0 ± 2.5 g; daily protein intake, 0.97 ± 0.18 g/kg; HbA1c, 8.3 ± 1.9%; blood lead levels (BLL), 4.3 ± 1.1 μg/dL; and body lead burden (BLB), 109.9 ± 52.3 μg

  • The results of the present study indicate that BLB and BLL, even at low levels, are important risk factors for progressive diabetic nephropathy

Read more

Summary

Introduction

Over the past 25 years, the prevalence of type II diabetes in the USA has almost doubled, with 3- to 5-fold increases in developing countries [1]. Few studies have investigated the relationship between environmental exposure to lead and diabetic nephropathy. Previous epidemiological studies [4,5,6] showed that blood lead levels (BLL) are related to renal function [4, 5] and exacerbated age-related decreases in renal function [6] in the general population, suggesting that environmental exposure to lead influences renal function in healthy individuals. Because BLL only indicates recent lead exposure [4, 7], body lead burden (BLB) is usually assessed by X-ray fluorescence to determine bone lead content and calcium disodium ethylenediaminetetraacetic acid (EDTA) mobilization tests [7]. Previous investigations that used EDTA mobilization tests to assess BLB in nondiabetic chronic kidney disease (CKD) patients with normal BLB [8,9,10,11,12] suggested that environmental lead exposure is associated with progressive CKD

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call